AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29062344 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to triage improvement
Number of subjects: 33
Study 26928521 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY‐TT (1 dose)
Number of subjects: 349
Study 26928521 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY‐TT (2 doses)
Number of subjects: 349
Study 26928521 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster dose of MenACWY‐TT
Number of subjects: 349
Study 26928521 — intervention group
Group type: COMPARATOR
Intervention: Primary MenACWY‐TT dose (age-matched, meningococcal naive children)
Number of subjects: 349
Study 26928521 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY‐TT
Number of subjects: 349
Study 24720919 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine (0.5 mg twice daily)
Number of subjects: 267
Study 24720919 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 267
Study 22524495 — intervention group
Group type: EXPERIMENTAL
Intervention: Judgements of retention (JORs)
Number of subjects: 0
Study 22524495 — intervention group
Group type: COMPARATOR
Intervention: Judgements of learning (JOLs)
Number of subjects: 0
Study 19934280 — intervention group
Group type: EXPERIMENTAL
Intervention: bupropion SR combined with brief counseling (group A)
Number of subjects: 205
Study 19934280 — intervention group
Group type: EXPERIMENTAL
Intervention: bupropion SR combined with nonspecific psychological support in groups (NSGS) (group B)
Number of subjects: 205
Study 19934280 — intervention group
Group type: EXPERIMENTAL
Intervention: bupropion SR combined with cognitive behavioral group therapy (CBGT) (group C)
Number of subjects: 205
Study 19934280 — intervention group
Group type: COMPARATOR
Intervention: CBGT as the only approach (group D)
Number of subjects: 205
Study 19934280 — intervention group
Group type: EXPERIMENTAL
Intervention: bupropion SR combined with NSGS (group B)
Number of subjects: 205
Study 19934280 — intervention group
Group type: EXPERIMENTAL
Intervention: bupropion SR combined with CBGT (group C)
Number of subjects: 205
Study 17258323 — intervention group
Group type: EXPERIMENTAL
Intervention: HAMD-17
Number of subjects: 113
Study 17258323 — intervention group
Group type: EXPERIMENTAL
Intervention: Short scales
Number of subjects: 113
Study 15340805 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 7.5%
Number of subjects: 100
Study 15340805 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (Control)
Number of subjects: 100
Study 11641310 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (2 mg) and Indapamide (0.625 mg)
Number of subjects: 471
Study 11641310 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (50 mg)
Number of subjects: 471
Study 9588696 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol (100 microg by patch)
Number of subjects: 15
Study 9588696 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone (100 mg i.m.)
Number of subjects: 15
Study 9588696 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 8108665 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone 50 mg per day for 14 days, then 25 mg per day for another 14 days.
Number of subjects: 93
Study 8108665 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets for the same time period (14 days of 50 mg, then 14 days of 25 mg).
Number of subjects: 93
Study 2697953 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser therapy using helium-neon, infrared, argon, and helium-cadmium lasers
Number of subjects: 300
Study 163938 — intervention group
Group type: EXPERIMENTAL
Intervention: ABOB 1% solution applied topically
Number of subjects: 151
Study 163938 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study 31113932 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO)
Number of subjects: 942
Study 31113932 — intervention group
Group type: COMPARATOR
Intervention: No Gemtuzumab ozogamicin (No-GO)
Number of subjects: 942
Study 28085204 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Resistance Training (PRT)
Number of subjects: 15
Study 28085204 — intervention group
Group type: COMPARATOR
Intervention: Aerobic Training (AT)
Number of subjects: 15
Study 28085204 — intervention group
Group type: COMPARATOR
Intervention: Control Group (AT)
Number of subjects: 15
Study 28085204 — intervention group
Group type: COMPARATOR
Intervention: Control Group (PRT)
Number of subjects: 15
Study 25433580 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium Fructoborate 112 mg/day (CFB-1)
Number of subjects: 0
Study 25433580 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium Fructoborate 56 mg/day (CFB-2)
Number of subjects: 0
Study 23515980 — intervention group
Group type: COMPARATOR
Intervention: Standard triple therapy (pantoprazole 40 mg, clarithromycin 500 mg, and amoxicillin 1 g each administered twice daily for 10 days)
Number of subjects: 272
Study 23515980 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential therapy (pantoprazole 40 mg plus amoxicillin 1 g twice daily for 5 days followed by pantoprazole 40 mg, clarithromycin 500 mg, and tinidazole 500 mg each administered twice daily for 5 days)
Number of subjects: 272
Study 23515980 — intervention group
Group type: COMPARATOR
Intervention: Standard triple therapy
Number of subjects: 272
Study 23515980 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential therapy
Number of subjects: 272
Study 23515980 — intervention group
Group type: EXPERIMENTAL
Intervention: Both therapies
Number of subjects: 272
Study 21749020 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-care program (face-to-face or telephone)
Number of subjects: 224
Study 21749020 — intervention group
Group type: COMPARATOR
Intervention: Control condition (educational)
Number of subjects: 224
Study 19916645 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intention formation
Number of subjects: 261
Study 19916645 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 261
Study 16961694 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg day(-1) micronized progesterone
Number of subjects: 49
Study 16961694 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg day(-1) oestradiol
Number of subjects: 49
Study 16961694 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of progesterone and oestradiol
Number of subjects: 49
Study 16961694 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 16961694 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal of hormone supplement
Number of subjects: 49
Study 15179374 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral glutamine feeding for 48 hours (20% of amino acids replaced with glutamine)
Number of subjects: 9
Study 15179374 — intervention group
Group type: COMPARATOR
Intervention: Conventional feeding (isonitrogenous, isocaloric standard enteral feedings for 48 hours)
Number of subjects: 9
Study 15179374 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral glutamine feeding for 48 hours
Number of subjects: 9
Study 11729008 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined psychotherapy and pharmacotherapy
Number of subjects: 0
Study 11729008 — intervention group
Group type: EXPERIMENTAL
Intervention: One-person treatment model (psychiatrist conducts psychotherapy and prescribes medication)
Number of subjects: 0
Study 9205763 — intervention group
Group type: EXPERIMENTAL
Intervention: ebrotidine (400 mg/day)
Number of subjects: 250
Study 9205763 — intervention group
Group type: COMPARATOR
Intervention: ranitidine (300 mg/day in healing phase, 150 mg/day in follow-up phase)
Number of subjects: 250
Study 8427866 — intervention group
Group type: EXPERIMENTAL
Intervention: Vessel wall shear stress calculated using a validated finite‐difference model of the Navier‐Stokes' equation with a coronary flow rate of 8 ml/sec.
Number of subjects: 20
Study 8427866 — intervention group
Group type: EXPERIMENTAL
Intervention: Low shear stress
Number of subjects: 20
Study 3629187 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 11
Study 3629187 — intervention group
Group type: COMPARATOR
Intervention: Aluminium-containing antacid
Number of subjects: 11
Study 30348912 — intervention group
Group type: EXPERIMENTAL
Intervention: VAMP-system flushing method
Number of subjects: 360
Study 30348912 — intervention group
Group type: COMPARATOR
Intervention: Traditional flushing method with 10 ml syringe of saline
Number of subjects: 360
Study 26774508 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide 160 mg/day
Number of subjects: 375
Study 26774508 — intervention group
Group type: COMPARATOR
Intervention: Bicalutamide 50 mg/day
Number of subjects: 375
Study 26774508 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Number of subjects: 375
Study 26774508 — intervention group
Group type: COMPARATOR
Intervention: Bicalutamide
Number of subjects: 375
Study 25015740 — intervention group
Group type: EXPERIMENTAL
Intervention: IORT as APBI according to ESTRO criteria
Number of subjects: 1108
Study 25015740 — intervention group
Group type: EXPERIMENTAL
Intervention: IORT as APBI according to ASTRO criteria
Number of subjects: 1108
Study 25015740 — intervention group
Group type: EXPERIMENTAL
Intervention: TARGIT E trial eligibility
Number of subjects: 1108
Study 25015740 — intervention group
Group type: EXPERIMENTAL
Intervention: TARGIT C trial eligibility
Number of subjects: 1108
Study 25015740 — intervention group
Group type: EXPERIMENTAL
Intervention: TARGIT BQR registry eligibility
Number of subjects: 1108
Study 25015740 — intervention group
Group type: EXPERIMENTAL
Intervention: IORT as APBI treatment
Number of subjects: 1108
Study 25015740 — intervention group
Group type: EXPERIMENTAL
Intervention: IORT boost treatment
Number of subjects: 1108
Study 22146934 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused imitation intervention
Number of subjects: 27
Study 22146934 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 27
Study 20691408 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation
Number of subjects: 38
Study 20691408 — intervention group
Group type: COMPARATOR
Intervention: Lecture
Number of subjects: 38
Study 20691408 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation→Lecture
Number of subjects: 38
Study 18936479 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-dose reirradiation combined with chemotherapy (RT arm)
Number of subjects: 130
Study 18936479 — intervention group
Group type: COMPARATOR
Intervention: Observation (wait and see approach; WS arm)
Number of subjects: 130
Study 15932528 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 0.1% dexamethasone eye drops four times daily (group A)
Number of subjects: 137
Study 15932528 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 0.1% dexamethasone eye drops twice daily (group B)
Number of subjects: 137
Study 15932528 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both groups
Number of subjects: 137
Study 12598253 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil alone
Number of subjects: 14
Study 12598253 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil combined with ketamine at 50 or 100 ng/mL
Number of subjects: 14
Study 12598253 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil at 2 ng/mL
Number of subjects: 14
Study 12598253 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 14
Study 10880799 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-positive subjects with CD4+ <200
Number of subjects: 56
Study 10880799 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-positive subjects with CD4+ >400
Number of subjects: 56
Study 10880799 — intervention group
Group type: COMPARATOR
Intervention: HIV-negative controls
Number of subjects: 56
Study 8979390 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-shot (high-risk, high-payoff) lottery preference
Number of subjects: 0
Study 8979390 — intervention group
Group type: COMPARATOR
Intervention: Rational analysis of lotteries
Number of subjects: 0
Study 8979390 — intervention group
Group type: EXPERIMENTAL
Intervention: Risky tendencies in unpleasant moods
Number of subjects: 0
Study 1734901 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose methotrexate (MTX) at a mean weekly dosage of 10.2 mg
Number of subjects: 26
Study 1734901 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose methotrexate (MTX)
Number of subjects: 26
Study 6524917 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate energy supplement (0 g protein, 420 kcal)
Number of subjects: 27
Study 6524917 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein supplement (14 g protein, 84 kcal)
Number of subjects: 27
Study 6524917 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 31862134 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrochemotherapy (ECT)
Number of subjects: 117
Study 31862134 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 117
Study 30335622 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental engagement during skin-to-skin contact (SSC)
Number of subjects: 28
Study 30335622 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal engagement scores during SSC
Number of subjects: 28
Study 30335622 — intervention group
Group type: EXPERIMENTAL
Intervention: Paternal oxytocin levels during SSC
Number of subjects: 28
Study 30335622 — intervention group
Group type: EXPERIMENTAL
Intervention: Paternal cortisol levels during SSC
Number of subjects: 28
Study 28801395 — intervention group
Group type: EXPERIMENTAL
Intervention: Question Prompt Sheet (QPS)
Number of subjects: 308
Study 28801395 — intervention group
Group type: COMPARATOR
Intervention: Question List (QL)
Number of subjects: 308
Study 28801395 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 308
Study 25579668 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary, coordinated and tailored RTW-intervention
Number of subjects: 168
Study 25579668 — intervention group
Group type: COMPARATOR
Intervention: Conventional case management
Number of subjects: 168
Study 23778773 — intervention group
Group type: EXPERIMENTAL
Intervention: Rib cage stabilization with an elastic band in the supine position
Number of subjects: 16
Study 23778773 — intervention group
Group type: EXPERIMENTAL
Intervention: Rib cage stabilization with an elastic band in the prone position
Number of subjects: 16
Study 23778773 — intervention group
Group type: COMPARATOR
Intervention: Supine position without the elastic band
Number of subjects: 16
Study 23778773 — intervention group
Group type: COMPARATOR
Intervention: Prone position without the elastic band
Number of subjects: 16
Study 21646823 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Intervention (MI) + Treatment as Usual (TAU)
Number of subjects: 62
Study 21646823 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 62
Study 19701513 — intervention group
Group type: EXPERIMENTAL
Intervention: Etch-and-rinse with 37% H3PO4 for 10 s (group 7)
Number of subjects: 0
Study 19701513 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermomechanical loading (TML)
Number of subjects: 0
Study 19701513 — intervention group
Group type: COMPARATOR
Intervention: No further pretreatment (group 5)
Number of subjects: 0
Study 19701513 — intervention group
Group type: COMPARATOR
Intervention: Use of a water cooled high-speed diamond bur (group 2)
Number of subjects: 0
Study 19701513 — intervention group
Group type: COMPARATOR
Intervention: Diamond bur and etching (group 4)
Number of subjects: 0
Study 19701513 — intervention group
Group type: COMPARATOR
Intervention: Syntac and two consecutive layers of Tetric flow (groups 6 and 8)
Number of subjects: 0
Study 16707195 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepavax-Gene TF
Number of subjects: 770
Study 16707195 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepavax-Gene
Number of subjects: 770
Study 16707195 — intervention group
Group type: COMPARATOR
Intervention: Engerix-B (control)
Number of subjects: 770
Study 11989841 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide 100 microg/h after an initial bolus of 100 microg plus terlipressin 2 mg
Number of subjects: 24
Study 11989841 — intervention group
Group type: COMPARATOR
Intervention: Terlipressin 2 mg
Number of subjects: 24
Study 11989841 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 10078672 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 10
Study 10078672 — intervention group
Group type: COMPARATOR
Intervention: Alfentanil
Number of subjects: 10
Study 10078672 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-pressor test
Number of subjects: 10
Study 10078672 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychomotor test 60 min after remifentanil infusion
Number of subjects: 10
Study 7733186 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgeon fixation
Number of subjects: 48
Study 7733186 — intervention group
Group type: COMPARATOR
Intervention: Patient fixation
Number of subjects: 48
Study 2342898 — intervention group
Group type: EXPERIMENTAL
Intervention: Waterbed flotation
Number of subjects: 22
Study 2342898 — intervention group
Group type: COMPARATOR
Intervention: Standard incubator mattress
Number of subjects: 22
Study 6106148 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol
Number of subjects: 7
Study 6106148 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 7
Study 6834205 — intervention group
Group type: EXPERIMENTAL
Intervention: Related play therapy
Number of subjects: 45
Study 6834205 — intervention group
Group type: EXPERIMENTAL
Intervention: Unrelated play therapy
Number of subjects: 45
Study 6834205 — intervention group
Group type: COMPARATOR
Intervention: Control (no preoperative preparation)
Number of subjects: 45
Study 29424008 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg granisetron
Number of subjects: 212
Study 29424008 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.7 mg granisetron
Number of subjects: 212
Study 29424008 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (control)
Number of subjects: 212
Study 29424008 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron groups (1 mg and 0.7 mg)
Number of subjects: 212
Study 29424008 — intervention group
Group type: COMPARATOR
Intervention: Group I (0.9% saline)
Number of subjects: 212
Study 29934199 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy plus standard care (10-14 sessions over 10 months)
Number of subjects: 255
Study 29934199 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 255
Study 26655732 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose cariprazine (1.5-4.5 mg/day)
Number of subjects: 0
Study 26655732 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cariprazine (6-12 mg/day)
Number of subjects: 0
Study 26655732 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24613434 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented milk (FM) 80 mL/d
Number of subjects: 24
Study 24613434 — intervention group
Group type: COMPARATOR
Intervention: Non-fermented milk (NFM) 80 mL/d
Number of subjects: 24
Study 22804104 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib or nonselective NSAID plus PPI
Number of subjects: 3774
Study 22804104 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline C-reactive protein (CRP) levels
Number of subjects: 3774
Study 22804104 — intervention group
Group type: EXPERIMENTAL
Intervention: History of gastritis
Number of subjects: 3774
Study 22804104 — intervention group
Group type: EXPERIMENTAL
Intervention: History of GI intolerance
Number of subjects: 3774
Study 22804104 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Helicobacter pylori at screening
Number of subjects: 3774
Study 22804104 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing age
Number of subjects: 3774
Study 22804104 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index (BMI)
Number of subjects: 3774
Study 20498097 — intervention group
Group type: EXPERIMENTAL
Intervention: Various treatments for low libido in women (specific interventions not detailed)
Number of subjects: 0
Study 18799936 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-D immunoglobulin (50 microg/kg)
Number of subjects: 0
Study 18799936 — intervention group
Group type: COMPARATOR
Intervention: intravenous immunoglobulin (IVIG, 1.0 g/kg/dose)
Number of subjects: 0
Study 15955958 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg of methylprednisolone (MP)
Number of subjects: 30
Study 15955958 — intervention group
Group type: EXPERIMENTAL
Intervention: 2,000 mg of methylprednisolone (MP)
Number of subjects: 30
Study 12025911 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized purified flavonoid fraction (MPFF) - 450 mg of micronized diosmin and 50 mg of flavonoids expressed in hesperidin for 6 months
Number of subjects: 5052
Study 12025911 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients with venous reflux)
Number of subjects: 5052
Study 10327189 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine (100 mg)
Number of subjects: 8
Study 10327189 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 8948610 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional interferon-gamma (IFN-G) injections
Number of subjects: 0
Study 8948610 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 0
Study 1721887 — intervention group
Group type: EXPERIMENTAL
Intervention: Isovolemic hemodilution over 6 weeks with hydroxyethyl starch solutions (PCV down to 35-32%)
Number of subjects: 21
Study 1721887 — intervention group
Group type: COMPARATOR
Intervention: Basic treatment of 75 mg of acetylsalicyclic acid daily
Number of subjects: 21
Study 6751656 — intervention group
Group type: EXPERIMENTAL
Intervention: 100-g oral glucose load after 3-hour exercise
Number of subjects: 0
Study 31377382 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted gait training (G-EO System), 20 sessions of 45 minutes each.
Number of subjects: 96
Study 31377382 — intervention group
Group type: COMPARATOR
Intervention: Treadmill training, 20 sessions of 45 minutes each.
Number of subjects: 96
Study 30174138 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating vitamin E levels
Number of subjects: 7781
Study 27567973 — intervention group
Group type: EXPERIMENTAL
Intervention: Child‐ and Family‐Focused Cognitive-Behavioral Therapy (CFF‐CBT)
Number of subjects: 69
Study 27567973 — intervention group
Group type: COMPARATOR
Intervention: Treatment As Usual (TAU)
Number of subjects: 69